Please use this identifier to cite or link to this item:
Title: Antiretroviral drugs: analysis of Ukrainian pharmaceutical market and intellectual property
Other Titles: Антиретровирусные препараты: анализ фармацевтического рынка Украины и патентной охраны
Антиретровірусні препарати: аналіз українського фармацевтичного ринку та патентної охорони
Authors: Litvinova, E. V.
Літвінова, О. В.
Литвинова, Е. В.
Posilikina, O. V.
Посилкіна, О. В.
Посылкина, О. В.
Keywords: Antiretroviral drug;intellectual property;patent;exclusivity data;антиретровирусные препараты;интеллектуальная собственность;патент;эксклюзивность;антиретровірусні препарати;інтелектуальна власність;патент;ексклюзивність
Issue Date: 2017
Publisher: Research Journal of Pharmacy and Technology
Bibliographic description (Ukraine): Litvinova, E. V. Antiretroviral drugs: analysis of Ukrainian pharmaceutical market and intellectual property / E. V. Litvinova, O. V. Posilkina // Research Journal of Pharmacy and Technology. – 2017. – Vol. 10. – № 7. – Р. 1–6.
Abstract: The aim of this study was to analyze Ukrainian pharmaceutical market and patent protection of antiretroviral drugs in Ukraine and abroad. It has established that in Ukraine most of medicines are foreign antiretroviral drugs under patent protection. Take into account the prevalence of HIV in Ukraine the introduction into clinical practice domestic generic antiretroviral drugs which included in clinical guidelines for the management of HIV and AIDS in adults and adoloscents and have obvious economic benefits is prospect and economically reasonable. It has found out that the most negative risks of commercialization antiretroviral drugs which influence on their access for patients with HIV are next risks: high cost of foreign antiretroviral drugs; lack of original domestic antiretroviral drugs; sharp rise in antiretroviral drug prices as a result of switch to second- and third line therapy; patent protection and monopolization of antiretroviral drugs; exclusivity data of clinical trials. It has proved that the use of the flexible mechanisms of the TRIPS Agreement in Ukraine, namely involving the grant of compulsory licenses, the implementation of parallel imports, the tightening of the criteria for patentability is necessary for increase of antiretroviral drugs access for patients with HIV infection.
Appears in Collections:Наукові публікації кафедри управління та забезпечення якості

Files in This Item:
File Description SizeFormat 
RJPT-4456--20-12-2016_1-1.pdf147,77 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.